Fig 2. Progression-free survival (PFS) of epidermal growth factor receptor mutant non-small-cell lung cancer patients treated with first-line tyrosine kinase inhibitors therapy.

(A) PFS between high and low baseline lymphocyte-to-monocyte ratio (LMR) patients; (B) PFS between high and low 1-month-to-baseline ratio of LMR (MBR) patients; (C) PFS between “high LMR and MBR”, “high LMR or MBR”, “low LMR and MBR” patients.